Seocalcitol.
Research-backed compound with potential health benefits. Acts like a targeted version of Vitamin D. It tells abnormal cells (like in some cancers or psoriasis) to stop growing so fast. Designed to do this without dangerously spiking your calcium.
Reviewed March 2026
- Category
- Compound
What Seocalcitol is, and what it does.
- Does it work
- It belongs to researchers and clinicians running trials rather than to a supplement shelf. Anyone thinking about everyday vitamin D nutrition is served by the dietary forms.
- How much to take
- Don't. Doses are determined by doctors in clinical trials for specific conditions. This isn't something to guess.
- Time to feel it
- Nobody has measured a subjective onset. In research settings the read-outs are blood calcium and gene expression markers tracked over weeks, so it shows in lab work.
- The first dose
- Nothing. In clinical trials, effects are measured over weeks and months by looking at biomarkers or skin lesions, not how you feel.
- With regular use
- In studies, it shows potential to slow the progression of certain cancers or clear up psoriatic plaques. But again, this is under strict medical supervision.
- How well tolerated
- Unknown for general use. In trials, it's considered safer than other Vitamin D analogs regarding calcium, but it's still a powerful drug with potential side effects.
- How it feels
- You don't feel it. It's a cellular signaling agent, not a stimulant or a calming agent. It works silently in the background.
- The overlooked benefit
- That unusual unsaturated tail is deliberate. It changes how fast the CYP24A1 enzyme clears the molecule, which is what separates an analogue's profile from the natural hormone.
5 to 10mcg a day is where Seocalcitol works.
Source: Vitamin D analog (EB1089). Dalhoff et al., Cancer Res, 2003; primarily oncology research
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Seocalcitol is documented in the library; the clinical read is in the queue. Nothing about the strength of the research prints until the read is done.
- vitamin D receptor activationIn vitro study
- calcium and phosphate handling by the gutNarrative review
- cell growth signalling in laboratory modelsIn vitro study
- resistance to CYP24A1 breakdown compared with the natural hormoneAnimal study
Questions people ask about Seocalcitol.
- Is this just a strong Vitamin D?
- No. It's a synthetic version designed to target cell growth with less effect on blood calcium. Think scalpel vs. hammer.
- Can I buy Seocalcitol online?
- You might see it on research chemical sites, but don't. You have no guarantee of purity, dose, or safety. Bad idea.
- Is it good for psoriasis?
- Topical versions have been studied for psoriasis and show promise. But this would be a prescription drug, not an over-the-counter supplement.
- What are the side effects?
- In trials, the main concern is always high blood calcium (hypercalcemia), though Seocalcitol is designed to minimize this. Other side effects are monitored by doctors.
- Can I take it with my Vitamin D3 supplement?
- Absolutely not. They both interact with the same receptors. Do not mix experimental drugs with supplements without a doctor's explicit guidance.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Seocalcitol is a vitamin D receptor agonist, and receptor activation turns on the intestinal calcium transport machinery. Calcium intake is what that raised transport capacity has to work with.
Cholecalciferol becomes calcitriol, the natural ligand for the same vitamin D receptor that seocalcitol binds. Their effects on calcium and phosphate handling add together rather than acting independently.
Calcifediol is the circulating store that is hydroxylated to the active receptor ligand. Stacking it with a receptor agonist raises total signalling through one shared pathway.
Eldecalcitol is another vitamin D receptor analog acting at the identical receptor. Two analogs together give one additive signal, so they count as a single load.
Vitamin D receptor activation raises production of osteocalcin and matrix Gla protein, both of which stay inert until vitamin K carboxylates their glutamate residues. K2 supplies the cofactor for the step that follows the vitamin D signal.
The hydroxylases that convert vitamin D compounds to their active form are magnesium-dependent. Low magnesium slows the whole vitamin D axis that the analog plugs into.
Vitamin D receptor activation raises intestinal phosphate absorption alongside calcium through the sodium-phosphate cotransporter. Phosphorus intake and analog dosing move the same serum mineral together.
Cholecalciferol is hydroxylated at carbon 25 in the liver and at carbon 1 in the kidney to reach the active hormone. A synthetic analogue bypasses those steps and acts directly at the receptor. Adding the parent nutrient on top raises total ligand pressure on the same axis, which matters for calcium handling. The relationship is settled vitamin D physiology.
An activated vitamin D receptor must dimerise with the retinoid X receptor before it can bind vitamin D response elements on DNA. Retinoid ligands that occupy the retinoid X receptor change the availability and conformation of that partner. The interaction is well characterised in nuclear receptor biology and is measured as transcriptional output, which is a marker rather than a clinical outcome.
Small human and animal studies report that boron intake changes circulating vitamin D metabolite concentrations, likely by slowing their catabolism. The effect is on the endogenous hormone rather than on a synthetic analogue. The evidence base is thin and the endpoint is a blood marker.
Strontium is absorbed through the same intestinal routes as calcium and deposits in the mineral phase of bone. A vitamin D receptor agonist raises the efficiency of that intestinal calcium route, which means strontium uptake moves with it. Strontium and calcium also compete with each other at absorption. This is established mineral physiology; nothing has measured the analogue with strontium directly.
Like other nuclear receptors, the vitamin D receptor grips its DNA response element through two zinc-coordinated finger motifs. Structural zinc is not consumed in the process, so ordinary status is enough, and this is not a reason to dose zinc alongside a receptor ligand. The relationship is structural biochemistry, stated so the mechanism is complete rather than as a formulation recommendation.
Nothing specific on file for Seocalcitol. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Seocalcitol actually does.
Seocalcitol is a synthetic secosteroid analogue of 1,25-dihydroxyvitamin D3 carrying a modified, unsaturated side chain, and it acts as an agonist at the nuclear vitamin D receptor.
An activated vitamin D receptor heterodimerises with the retinoid X receptor and binds vitamin D response elements in DNA, which is how any ligand of this class changes gene transcription.
Vitamin D receptor agonists raise intestinal calcium absorption by inducing the calcium transport machinery of the enterocyte, so any ligand of this class shifts calcium and phosphate handling.
Side-chain modification of the secosteroid skeleton is the standard medicinal-chemistry route to changing how fast the CYP24A1 enzyme degrades the molecule, which is what separates an analogue's profile from that of the natural hormone.
Where Seocalcitol comes from.
This one is made in a chemistry plant, not harvested. Chemists start from the same ring structure vitamin D has, attach a different tail, add the two hydroxyl groups the body would normally add itself, then separate the right version from close look-alikes.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
The starting point is the seco-steroid ring system shared with cholecalciferol chemistry, obtained from steroid feedstocks rather than from any plant or animal extract.
The modified, unsaturated side chain that defines this analogue is built separately and coupled to the ring fragment, the standard convergent approach used for vitamin D analogues.
The A ring hydroxyl pattern that lets the molecule bind the receptor is installed chemically rather than by the liver and kidney enzymes that process dietary vitamin D.
Secosteroid syntheses generate geometric and stereochemical isomers, so preparative chromatography and controlled crystallisation are needed to isolate the intended compound.
Release testing confirms structure and isomeric purity, since the biological profile of a vitamin D analogue is highly sensitive to stereochemistry.
The essence, in one line each.
- A computational docking and molecular dynamics analysis reports that seocalcitol binds the vitamin D receptor ligand pocket and also docks against ACE2, which the authors present as a modelling hypothesis for further work.In vitro study. Kaur S et al., 2024 (Bioinformation). PMID 42186536 ↗
These are the studies our verdict leans on, chosen from the 1 we read for Seocalcitol. The full linked list is below.
The studies, linked.
2 sources behind our Seocalcitol verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialSeocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma. Efficacy of Seocalcitol (EB 1089) Enteric-Coated Capsules (5ug) or Placebo in the Treatment of Patients With Hepatocellular Carcinoma Not Amenable to Curative TreatmentClinicalTrials.gov ↗NA · 700 participants · Terminated
- Clinical trialSeocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma. Efficacy of Seocalcitol (EB 1089) Enteric-Coated Capsules (5 ug) or Placebo in Prolonging Time to Relapse Following Intended Curative Resection or Percutaneous Ablative Treatment for Hepatocellular CarcinomaClinicalTrials.gov ↗PHASE3 · 608 participants · Terminated
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.